Avexa Limited Secures CCR5 Inhibitor HIV Program With TargetDrug

VICTORIA, Australia--(BUSINESS WIRE)--Avexa (ASX:AVX) today announced the completion and formalisation of the licensing and collaboration agreement on a CCR5 HIV drug program with TargetDrug of Shanghai on terms as announced on 4 December 2006. Avexa and TargetDrug have already commenced the collaborative phase of the agreement aimed at the identification of new and improved clinical candidates from the program.